Pharmacy 3D printing
Source abstract
Abstract
Abstract A significant limitation of the ‘one size fits all’ medication approach is the lack of consideration for special population groups. 3D printing technology has revolutionised the landscape of pharmaceuticals and pharmacy practice, playing an integral role in enabling on-demand production of customised medication. Compared to traditional pharmaceutical processes, 3D printing has major advantages in producing tailored dosage forms with unique drug release mechanisms. Moreover, this technology has enabled the combination of multiple drugs in a single formulation addressing key issues of medication burden. Development of 3D printing in pharmacy applications and large-scale pharmaceutical manufacturing has substantially increased in recent years. This review focuses on the emergence of extrusion-based 3D printing, particularly semi solid extrusion, fused deposition modelling and direct powder extrusion, which are currently the most commonly studied for pharmacy practice. The concept of each technique is summarised, with examples of current and potential applications. Next, recent advancements in the 3D printer market and pharmacist perceptions are discussed. Finally, the benefits, challenges and prospects of pharmacy 3D printing technology are highlighted, emphasising its significance in changing the future of this field.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Additive Manufacturing and 3D Printing Technologies · Injection Molding Process and Properties · 3D Printing in Biomedical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. 3D printing technology: a new approach for the fabrication of personalized and customized pharmaceuticals10.1016/j.eurpolymj.2023.112240 ↗
2. 3D printing for personalised medicines: implications for policy and practice10.1016/j.ijpharm.2023.122785 ↗
3. The frequency of inappropriate tablet splitting in primary care10.1007/s00228-006-0202-3 ↗
4. The practice and clinical implications of tablet splitting in international health10.1111/tmi.12309 ↗
5. Evaluation of certain pharmaceutical quality attributes of lisinopril split tablets10.3390/scipharm84040646 ↗
6. The accuracy, precision and sustainability of different techniques for tablet subdivision: breaking by hand and the use of tablet splitters or a kitchen knife10.1016/j.ijpharm.2014.02.031 ↗
7. Content uniformity of quartered hydrocortisone tablets in comparison with mini-tablets for paediatric dosing10.1136/bmjpo-2017-000198 ↗
8. Accuracy of tablet splitting: comparison study between hand splitting and tablet cutter10.1016/j.jsps.2013.12.014 ↗
9. Does splitting a tablet obtain an accurate dose? A systematic review and meta‐ analysis10.1002/jppr.1843 ↗
10. Dose form modification—a common but potentially hazardous practice. A literature review and study of medication administration to older psychiatric inpatients10.1017/S1041610207006047 ↗
11. Potential risks of pharmacy compounding10.1007/s40268-013-0005-9 ↗
12. Pharmaceutical compounding: a history, regulatory overview, and systematic review of compounding errors10.1007/s13181-020-00814-3 ↗
13. Clonidine compounding error: bradycardia and sedation in a pediatric patient10.1016/j.jemermed.2020.04.027 ↗
14. Medication dose calculation errors and other numeracy mishaps in hospitals: analysis of the nature and enablers of incident reports10.1111/jan.15072 ↗
15. Additive manufacturing technologies: industrial and medical applications10.1016/j.susoc.2022.05.001 ↗
16. Scenarios for 3D printing of personalized medicines—A case study10.1016/j.rcsop.2021.100073 ↗
17. Opportunities and challenges of three-dimensional printing technology in pharmaceutical formulation development10.1016/j.apsb.2021.03.015 ↗
18. A review of 3D printing technology in pharmaceutics: technology and applications, now and future10.3390/pharmaceutics15020416 ↗
19. 3D printing in the pharmaceutical sector: advances and evidences10.1016/j.sintl.2022.100177 ↗
20. Formulation and characterization of immediate-release oral dosage forms with zolpidem tartrate fabricated by digital light processing (DLP) 3D printing technique10.1016/j.ijpharm.2022.122046 ↗
21. Fabrication of gastro-floating famotidine tablets: hydroxypropyl methylcellulose-based semisolid extrusion 3D printing10.3390/pharmaceutics15020316 ↗
22. 3D printing of extended-release tablets of theophylline using hydroxypropyl methylcellulose (HPMC) hydrogels10.1016/j.ijpharm.2020.119983 ↗
23. Pharmaceutical applications of 3D printing10.1016/j.addma.2020.101209 ↗
24. 3D printed drug delivery and testing systems—a passing fad or the future?10.1016/j.addr.2018.05.006 ↗
25. Fused deposition modeling (FDM), the new asset for the production of tailored medicines10.1016/j.jconrel.2020.10.056 ↗
26. Recent progress in three-dimensionally-printed dosage forms from a pharmacist perspective10.1093/jpp/rgab168 ↗
27. Recent progress on polymer materials for additive manufacturing10.1002/adfm.202003062 ↗
28. 3D printing in medicine: technology overview and drug delivery applications10.1016/j.stlm.2021.100037 ↗
29. 3D printing in pharmaceutical and medical applications—recent achievements and challenges10.1007/s11095-018-2454-x ↗
30. The recent development of vat photopolymerization: a review10.1016/j.addma.2021.102423 ↗
31. Lessons from nature: 3D printed bio-inspired porous structures for impact energy absorption—A review10.1016/j.addma.2022.103051 ↗
32. The state of the art of material jetting-A critical review10.3390/polym13162829 ↗
33. Binder jet 3D printing—Process parameters, materials, properties, modeling, and challenges10.1016/j.pmatsci.2020.100707 ↗
34. Automated manufacturing and processing of fiber-reinforced polymer (FRP) composites: an additive review of contemporary and modern techniques for advanced materials manufacturing10.1016/j.addma.2017.01.003 ↗
35. Additive manufacturing in the aerospace and automotive industries: recent trends and role in achieving sustainable development goals10.1016/j.asej.2023.102516 ↗
36. 3D printing pharmaceuticals: drug development to frontline care10.1016/j.tips.2018.02.006 ↗
37. Three-dimensional printing in pharmaceutics: promises and problems10.1002/jps.21284 ↗
38. Revolutionizing manufacturing: a comprehensive overview of additive manufacturing processes, materials, developments, and challenges10.1016/j.jmapro.2023.10.024 ↗
39. Polymers for extrusion-based 3D printing of pharmaceuticals: a holistic materials–process perspective10.3390/pharmaceutics12020124 ↗
40. Extrusion-based additive manufacturing technologies: state of the art and future perspectives10.1016/j.jmapro.2022.09.032 ↗
41. Semi-solid extrusion 3D printing in drug delivery and biomedicine: personalised solutions for healthcare challenges10.1016/j.jconrel.2021.02.027 ↗
42. An overview of 3D printing technologies for soft materials and potential opportunities for lipid-based drug delivery systems10.1007/s11095-018-2531-1 ↗
43. Additive manufacturing (3D printing): a review of materials, methods, applications and challenges10.1016/j.compositesb.2018.02.012 ↗
44. 3D printing direct powder extrusion in the production of drug delivery systems: state of the art and future perspectives10.3390/pharmaceutics16040437 ↗
45. Automated and dynamic extrusion pressure adjustment based on real-time flow rate measurements for precise ink dispensing in 3D bioprinting10.1016/j.bprint.2022.e00229 ↗
46. Current advances and future perspectives in extrusion-based bioprinting10.1016/j.biomaterials.2015.10.076 ↗
47. Three-dimensional, soft magnetic-cored solenoids via multi-material extrusion10.1080/17452759.2024.2310046 ↗
48. Integrating pressure sensor control into semi-solid extrusion 3D printing to optimize medicine manufacturing10.1016/j.ijpx.2022.100133 ↗
49. A feasibility study of an extrusion-based fabrication process for personalized drugs10.3390/jpm10010016 ↗
50. Hydroxypropyl-β-cyclodextrin-based fast dissolving carbamazepine printlets prepared by semisolid extrusion 3D printing10.1016/j.carbpol.2019.05.084 ↗
51. A tunable extruded 3D printing platform using thermo-sensitive pastes10.1016/j.ijpharm.2020.119360 ↗
52. Effect of novel internal structures on printability and drug release behavior of 3D printed tablets10.1016/j.jddst.2018.10.037 ↗
53. 3D printed, controlled release, tritherapeutic tablet matrix for advanced anti-HIV-1 drug delivery10.1016/j.ejpb.2018.04.007 ↗
54. Investigation of semi-solid formulations for 3D printing of drugs after prolonged storage to mimic real-life applications10.1016/j.ejps.2020.105266 ↗
55. A micro-extrusion 3D printing platform for fabrication of orodispersible printlets for pediatric use10.1016/j.ijpharm.2021.120854 ↗
56. Semi-solid extrusion 3D printing ODFs: an individual drug delivery system for small scale pharmacy10.1080/03639045.2020.1734018 ↗
57. Preparation and application of subdivided tablets using 3D printing for precise hospital dispensing10.1016/j.ejps.2020.105293 ↗
58. Improving the quality and clinical efficacy of subdivided levothyroxine sodium tablets by 3D printing technology10.1016/j.jddst.2023.105008 ↗
59. Automated therapy preparation of isoleucine formulations using 3D printing for the treatment of MSUD: first single-centre, prospective, crossover study in patients10.1016/j.ijpharm.2019.118497 ↗
60. Cereal-based 3D printed dosage forms for drug administration during breakfast in pediatric patients within a hospital setting10.1016/j.xphs.2022.04.013 ↗
61. Towards printed pediatric medicines in hospital pharmacies: comparison of 2D and 3D-printed orodispersible warfarin films with conventional oral powders in unit dose sachets10.3390/pharmaceutics11070334 ↗
62. Additive manufacturing of personalized orodispersible warfarin films10.1016/j.ijpharm.2019.04.018 ↗
63. A 3D-printed local drug delivery patch for pancreatic cancer growth suppression10.1016/j.jconrel.2016.06.015 ↗
64. Experimental investigation on the application of FDM 3D printed conductive ABS-CB composite in EMI shielding10.1016/j.radphyschem.2022.110263 ↗
65. A comprehensive review of FDM printing in sensor applications: advancements and future perspectives10.1016/j.jmapro.2024.01.030 ↗
66. A study on fused deposition modeling (FDM) and laser-based additive manufacturing (LBAM) in the medical field10.1016/j.ipha.2024.02.010 ↗
67. Additive manufacturing with 3D printing: progress from bench to bedside10.1208/s12248-018-0225-6 ↗
68. Influence of 3D printing FDM process parameters on tensile property of ULTEM 908510.1016/j.promfg.2019.02.047 ↗
69. Modelling the process of fused deposition modelling and the effect of temperature on the mechanical, roughness, and porosity properties of resulting composite products10.1007/s11029-021-09925-6 ↗
70. Development of 3D-printed bicompartmental devices by dual-nozzle fused deposition modeling (FDM) for colon-specific drug delivery10.3390/pharmaceutics15092362 ↗
71. Fused-filament 3D printing (3DP) for fabrication of tablets10.1016/j.ijpharm.2014.09.044 ↗
72. Fused deposition modelling: current status, methodology, applications and future prospects10.1016/j.addma.2021.102378 ↗
73. Design, preparation and in vitro evaluation of core–shell fused deposition modelling 3D-printed verapamil hydrochloride pulsatile tablets10.3390/pharmaceutics14020437 ↗
74. A case study to investigate the influence of extrusion temperature, 3D printing parameters and the use of antioxidants on the degradation of dexamethasone10.1016/j.jddst.2024.105394 ↗
75. Low temperature fused deposition modeling (FDM) 3D printing of thermolabile drugs10.1016/j.ijpharm.2018.04.055 ↗
76. Expandable drug delivery system for gastric retention based on shape memory polymers: development via 4D printing and extrusion10.1016/j.ijpharm.2019.118700 ↗
77. Comparison of fused-filament fabrication to direct compression and injection molding in the manufacture of oral tablets10.1016/j.ijpharm.2019.01.013 ↗
78. 3D floating tablets: appropriate 3D design from the perspective of different in vitro dissolution testing methodologies10.1016/j.ijpharm.2019.06.024 ↗
79. Poly(vinyl alcohol) 3D printed tablets: the effect of polymer particle size on drug loading and process efficiency10.1016/j.ijpharm.2019.02.025 ↗
80. Exploring tablet design options for tailoring drug release and dose via fused deposition modeling (FDM) 3D printing10.1016/j.ijpharm.2020.119987 ↗
81. Development of FDM 3D-printed tablets with rapid drug release, high drug-polymer miscibility and reduced printing temperature by applying the acid-base supersolubilization (ABS) principle10.1016/j.ijpharm.2021.120524 ↗
82. 3D-printed isoniazid tablets for the treatment and prevention of tuberculosis—Personalized dosing and drug release10.1208/s12249-018-1233-7 ↗
83. Fabrication of zero-order sustained-release floating tablets via fused depositing modeling 3D printer10.1248/cpb.c19-00290 ↗
84. ‘Temporary Plasticiser’: a novel solution to fabricate 3D printed patient-centred cardiovascular ‘Polypill’ architectures10.1016/j.ejpb.2018.12.009 ↗
85. Tablet fragmentation without a disintegrant: a novel design approach for accelerating disintegration and drug release from 3D printed cellulosic tablets10.1016/j.ejps.2018.03.019 ↗
86. Application of 3D printing technology for generating hollow-type suppository shells10.1016/j.ijpharm.2020.119825 ↗
87. Manipulating drug release from 3D printed dual-drug loaded polypills using challenging polymer compositions10.1016/j.ijpharm.2023.122895 ↗
88. Feasibility study into the potential use of fused-deposition modeling to manufacture 3D-printed enteric capsules in compounding pharmacies10.1016/j.ijpharm.2019.118581 ↗
89. Design and characterization of a novel 3D printed pressure-controlled drug delivery system10.1016/j.ejps.2019.105060 ↗
90. 3D printed mini-floating-polypill for parkinson’s disease: combination of levodopa, benserazide, and pramipexole in various dosing for personalized therapy10.3390/pharmaceutics14050931 ↗
91. Processing thermally labile drugs by hot-melt extrusion: the lesson with gliclazide10.1016/j.ejpb.2017.05.014 ↗
92. Development of subdermal implants using direct powder extrusion 3D printing and hot-melt extrusion technologies10.1208/s12249-023-02669-7 ↗
93. A large‐scale double‐stage‐screw 3D printer for fused deposition of plastic pellets10.1002/app.45147 ↗
94. Feasibility study of the use of a homemade direct powder extrusion printer to manufacture printed tablets with an immediate release of a BCS II molecule10.1016/j.ijpharm.2023.123506 ↗
95. Direct powder extrusion 3D printing of praziquantel to overcome neglected disease formulation challenges in paediatric populations10.3390/pharmaceutics13081114 ↗
96. Direct powder extrusion 3D printing: fabrication of drug products using a novel single-step process10.1016/j.ijpharm.2019.118471 ↗
97. Development of an immediate release excipient composition for 3D printing via direct powder extrusion in a hospital10.1016/j.ijpharm.2023.123218 ↗
98. 3D printed mucoadhesive orodispersible films manufactured by direct powder extrusion for personalized clobetasol propionate based paediatric therapies10.1016/j.ijpharm.2023.123214 ↗
99. Preparation of core-shell controlled release tablets using direct powder extrusion 3D printing techniques10.1016/j.jddst.2023.104896 ↗
100. 3D printed opioid medicines with alcohol-resistant and abuse-deterrent properties10.1016/j.ijpharm.2020.119169 ↗